Narrative review on therapeutic cancer vaccines for head and neck squamous cell carcinoma

This is a narrative review that synthesizes existing evidence on therapeutic cancer vaccines for head and neck squamous cell carcinoma (HNSCC). The scope includes personalized cancer vaccines and their combination with immune checkpoint inhibitor therapy. The authors discuss the current state of research, noting that clinical data are limited and no specific efficacy outcomes or pooled effect sizes are reported. The review highlights the theoretical potential of these approaches but emphasizes that evidence is preliminary. Key limitations noted include the lack of reported primary outcomes, sample sizes, or follow-up data in the source literature. The authors do not report specific safety data or practice guidelines. The review suggests that while vaccine-based strategies are an active area of investigation, their clinical role in HNSCC remains undefined and requires further rigorous study. Practice relevance is not specified, and the authors caution against overinterpreting the available evidence.